• About us
• Contact

Advertisement

Organisation › Details

Visikol Inc.

Visikol is a CRO focused on advanced drug discovery that is leading the fields of bio-imaging, bioinformatics and image analysis. We conduct end-to-end drug discovery services that include both 2D and 3D in vitro models and assays, 3D whole mount tissue imaging, digital pathology and custom drug discovery projects. Visikol offers a portfolio of drug discovery services ranging from 2D and 3D cell culture model and assay development to in vitro screening, animal tissue histology and automated image processing. The focus of these services is to transform tissues into images and ultimately into quantitative data sets that can be mined for actionable insights that help our Clients make more informed decisions during the drug discovery process. Additionally, Visikol manufactures and sells a suite of tissue clearing reagents and 3D immuno-labeling kits. These products allow researchers to easily and rapidly image whole tissues and 3D cell culture models in 3D instead of traditional 2D sectioning. *

 

	Start	2020-05-07 existent
	Industry	mass cytometry services
	Person	Johnson, Michael (Visikol 202005 CEO)
	Street	53 Frontage Road Shelbourne Building, Suite 120
	City	08827 Hampton, NJ
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
		* Document for »About Section«: Fluidigm Corporation. (5/7/20). "Press Release: Fluidigm Expands Accessibility of Mass Cytometry and Imaging Mass Cytometry Technology with New Therapeutic Insights Services". South San Francisco, CA.
		Record changed: 2023-07-10

Advertisement

More documents for Bico (Group)

• [1] Bico Group AB. (11/21/24). "Press Release: Bico Has Entered into an Agreement to Divest Nanoscribe"....
• [2] Bico Group AB. (3/15/24). "Press Release: Founders Leave after Eight Years"....
• [3] Bico Group AB. (11/13/23). "Press Release: BICO Has Divested Ginolis through a Management Buy-out to Ginolis’ Current CEO Kauko Väinämö. The Purchase Price amounted to €1"....
• [4] Bico Group AB. (11/13/23). "Press Release: Maria Forss Assumes Office as BICO’s CEO and President on November 20, 2023"....
• [5] Scienion AG. (9/13/22). "Press Release: Scienion and Cellenion Launch the proteoCHIP LF 48, for Label-free Single-cell Proteomics Sample Preparation on the cellenONE platform". Berlin & Lyon....
• [6] Scienion GmbH. (6/1/22). "Press Release: Scienion Appoints Frauke Hein as CEO". Berlin....
• [7] Bico Group AB. (11/17/21). "Press Release: Bico Announces Appointment of Susan Tousi as New Member of the Board of Directors"....
• [8] Bico Group AB. (11/16/21). "Press Release: Cellenion Announces Co-marketing Agreement with Bruker to Deliver Advanced Solutions for Single Cell Mass Spectrometry-based Proteomics Analysis"....
• [9] Bico Group AB. (11/15/21). "Press Release: Cellenion Announces Co-marketing Agreement for Single Cell Mass Spectrometry-based Proteomics Analysis"....
• [10] Bico Group AB. (10/15/21). "Press Release: Bico Completes the Acquisition of QInstruments"....

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2025. Made in Germany.